吕跃 - 中山大学 - 肿瘤防治中心

个人简介

学习及工作经历： 1982年:毕业于中国医科大学医学部 1991年—1996年：日本札幌医科大学附属医院第四内科、获日本医学博士学位 2003年—2009年：中山大学附属肿瘤医院肿瘤内科教授、主任医师；中山大学肿瘤防治中心白血病及骨髓瘤研究中心主任 2009年至今：中山大学附属肿瘤医院血液肿瘤科主任、教授、主任医师

研究领域

新的血液肿瘤临床诊断和治疗方法研究肿瘤转移治疗及预防的研究肿瘤分子诊断及基因靶向和免疫生物治疗研究

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Wang L, Liu P, Chen X, Geng Q, Lu Y(通讯作者). Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Med Oncol. 2011 Aug 30. [Epub ahead of print] （SCI）　　2. Wang H, Chen XQ, Geng QR, Liu PP, Lin GN, Xia ZJ, Lu Y(通讯作者). Induction therapy using the MRC UKALLXII/ECOG E2993 protocol in Chinese adults with acute lymphoblastic leukemia. Int J Hematol. 2011 Aug;94(2):163-8. Epub 2011 Jul 6.（SCI）　　3. Wang L, Liu P, Geng Q, Chen X, Lv（u）Y(通讯作者). Prognostic significance of neuron-specific enolase in patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Leuk Lymphoma. 2011 Sep;52(9):1697-703. Epub 2011 Aug 4.（SCI）　　4. Wang L， Lin G， Jiang XL，Lu Y (通讯作者). Expression of ezrin correlates with poor prognosis of nasopharyngeal carcinoma. Tumour Biol. 2011 Aug;32(4):707-12. Epub 2011 Apr 6.（SCI）　　5. Wang G, Chen XQ, Geng QR, Li J,Lin GN,Lu Y(通讯作者). As2O3overcome cell adhesion mediated drug resistance (CAM-DR) through down-regulatingthe expression of β1-integrin in K562 chronic myelogenous leukemia cell line.Leukemia and Lymphoma.June 2010; 51(6): 1090–1097.(SCI)　　6. Huang JJ, Xia Y, Zhu YJ, Lin TY, Li ZM, Jiang WQ, Xu RH, Huang HQ, Lv（u）Y, Sun XF, Xia ZJ.Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients.Med Oncol. 2010 Aug 31.[Epub ahead of print]（SCI）　　7. Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, Lv（u）Y, Xia ZJ, Zhu XF, Lin TY, Li ZM.Beclin 1expression: a predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type.Autophagy. 2010 Aug 16;6(6):777-83. （SCI）　　8. Huang J, Jiang W, Xu R, Huang H, Lv(u) Y, Xia Z, Sun X, Guan Z, Lin T, Li Z.Primarygastric non-Hodgkin''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''s lymphoma in Chinese patients: clinical characteristics and prognostic factors.BMC Cancer. 2010 Jul 6;10:358. （SCI）　　9. Li X，Lu Y（通讯作者）, WenLin Huang , HaiPeng Xu , XiaoQin Chen , QiRong Geng.In vitro effect of adenovirus-mediated Human Gamma Interferon Gene Transfer into Human Mesenchymal Stem Cells for Chronic Myelogenous Leukemia. Hematological Oncology. Hematol Oncol. 2006; 24: 151–8.（SCI）　　10.Lu Y,Skamaki S,Hiroyuki Kuroda,Toshiro Kusakabe,Yuichi Konuma,Takehide Akiyama, Akihito Fujimi,Naofumi Takemoto,Kyokusen Nishiie,Takuya Matsunaga,Yasuo Hirayama,Junji Kato,ShinichiroKon,KatsuhisaKogawa,and Yoshiro Niitsu. Complete preventionof acute lethal GVHD by newly synthesyzed Th1- specific inhibitor-TAK603 in mice.Blood. 97:1123-1130, 2001.（SCI）　　11. Lu Y, Yamauchi N，Koshita Y, Fujiwara H, Sato Y, Fujii S, Takahashi M, Sato T,Kato J, Yamagishi H, Niitsu Y.Administration of sub tumor-regression dosage of TNF to mice with preexisting parental tumors augments the vaccination effect of TNF gene modified tumorthrough the induction of MHC class I molecule. Gene Therapy.8：499-507，2001.（SCI）　　12.Takahashi M，Sato T，Sagawa T，Lu Y，Sato Y, Iyama S, Yamada Y, Fukaura J, Takahashi S, Miyanishi K, Yamashita T, Sasaki K, Kogawa K, Hamada H, Kato J, Niitsu Y.E1B-55K deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Molecular Therapy.5:627-634,2002.（SCI）　　13.Sagawa T, Takahashi M, Sato T, Sato Y, Lu Y，Sumiyoshi T, Yamada Y, Iyama S, Fukaura J,Sasaki K, Hamada H, Miyanishi K, Takayama T, Kato J, Niitsu Y. Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter. Molecular Therapy.10(6):1043-50, 2004.（SCI）　　14.Koshita Y, Lu Y, Fujii S, Neda H, Matsuyama T, Satoh Y, Itoh Y, Takahashi M, Kato J, Sakamaki S, Niitsu Y. Efficacy of TNF-alpha gene-transduced tumor cells intreatment of established in vivo tumor. International Journal of Cancer. 63:130-5, 1995.（SCI）　　15.Lu Y, Koushita Y et al. Upregulation of Class II and B7 on tumor cell surface in thymidine kinase gene therapy for animals with low immune response. Biotherapy. 13:721-730,1999.　　16.Lu Y, Koushita Y et al. Studies on utility and side effects of thymidine kinase gene therapy in mice with multiple metastasis. Sapporo Medical Journal. 65:10-22, 1996.